Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy

Open access
Perricone, Carlo, Bartoloni, Elena, Bursi, Roberto, Cafaro, Giacomo, Guidelli, Giacomo Maria, Shoenfeld, Yehuda, Gerli, Roberto·2020·Immunologic Research

Abstract

SARS-CoV-2 infection is characterized by a protean clinical picture that can range from asymptomatic patients to life-threatening conditions. Severe COVID-19 patients often display a severe pulmonary involvement and develop neutrophilia, lymphopenia, and strikingly elevated levels of IL-6. There is an over-exuberant cytokine release with hyperferritinemia leading to the idea that COVID-19 is part of the hyperferritinemic syndrome spectrum. Indeed, very high levels of ferritin can occur in other diseases including hemophagocytic lymphohistiocytosis, macrophage activation syndrome, adult-onset Still’s disease, catastrophic antiphospholipid syndrome and septic shock. Numerous studies have demonstrated the immunomodulatory effects of ferritin and its association with mortality and sustained inflammatory process. High levels of free iron are harmful in tissues, especially through the redox damage that can lead to fibrosis. Iron chelation represents a pillar in the treatment of iron overload. In addition, it was proven to have an anti-viral and anti-fibrotic activity. Herein, we analyse the pathogenic role of ferritin and iron during SARS-CoV-2 infection and propose iron depletion therapy as a novel therapeutic approach in the COVID-19 pandemic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12026-020-09145-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 104

  1. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. [Online ahead of print]. https://doi.org/10.1056/NEJMoa2002032. · DOI · Paper page
  2. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020. [Online ahead of print]. https://doi.org/10.1001/jama.2020.378. · doi:10.1001/jama.2020.378
  3. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95–103. · DOI · Paper page
  4. Wang WK, Chen SY, Liu IJ, Kao CL, Chen HL, Chiang BL, et al. Severe acute respiratory syndrome research Group of the National Taiwan University College of Medicine/NTU Hospital. Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis. 2004;39:1071–5. · DOI
  5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3. · DOI · Paper page
  6. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:1.
  7. Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Inf Secur. 2020;80:394–400.
  8. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–39. · DOI · Paper page
  9. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–94. · DOI · Paper page
  10. Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343:172–8. · DOI · Paper page
  11. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4. · DOI · Paper page
  12. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10:55. · DOI · Paper page
  13. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6:457–63. · DOI · Paper page
  14. Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H, Szekanecz Z, et al. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol. 2011;44:23–30. · DOI
  15. Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csepany T, Danko K, Shapira Y, et al. Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J. 2011;13:91–5.
  16. Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007;1109:385–400. · DOI · Paper page
  17. Bennett TD, Hayward KN, Farris RW, Ringold S, Wallace CA, Brogan TV. Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care Med. 2011;12:e233–6. · DOI
  18. Garcia PC, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin levels in children with severe sepsis and septic shock. Acta Paediatr. 2007;96:1829–31. · DOI
  19. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10:387–92. · DOI · Paper page
  20. Grangé S, Buchonnet G, Besnier E, Artaud-Macari E, Beduneau G, Carpentier D, et al. The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Crit Care Med. 2016 Nov;44(11):e1045–53. · doi:10.1097/ccm.0000000000001878
  21. Lachmann G, Knaak C, Vorderwülbecke G, la Rosée P, Balzer F, Schenk T, et al. Hyperferritinemia in critically ill patients. Crit Care Med. 2020;48(4):459–65. · doi:10.1097/ccm.0000000000004131
  22. Betancur JF, Navarro EP, Echeverry A, Moncada PA, Cañas CA, Tobón GJ. Hyperferritinemic syndrome: Still's disease and catastrophic antiphospholipid syndrome triggered by fulminant Chikungunya infection: a case report of two patients. Clin Rheumatol. 2015;34:1989–92. · doi:10.1007/s10067-015-3040-9
  23. Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, et al. Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol. 2020;146:1065–77. · DOI
  24. Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. Int Immunol. 2018;30:195–203. · DOI
  25. Ruscitti P, Cipriani P, Ciccia F, Di Benedetto P, Liakouli V, Berardicurti O, et al. H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still’s disease patients and correlate with the multi-visceral involvement of the disease. Clin Exp Immunol. 2016;186:30–8. · DOI
  26. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185. · DOI · Paper page
  27. Carcillo JA, Simon DW, Podd BS. How we manage hyperferritinemic sepsis-related multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis histiocytosis. Pediatr Crit Care Med. 2015;16:598–600. · DOI
  28. Schaffner M, Rosenstein L, Ballas Z, Suneja M. Significance of hyperferritinemia in hospitalized adults. Am J Med Sci. 2017;354:152–8. · DOI
  29. Saeed H, Woods RR, Lester J, Herzig R, Gul Z, Monohan G. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting. Int J Hematol. 2015;102(2):195–9. · DOI
  30. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133:2465–77. · DOI · Paper page
  31. Wang H, Xiong L, Tang W, Zhou Y, Li F. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget. 2017;8:59977–85. · DOI
  32. Danhaive O, Caniglia M, Devito R, Piersigilli F, Corchia C, Auriti C. Neonatal liver failure and haemophagocytic lymphohistiocytosis caused by a new perforin mutation. Acta Paediatr. 2010;99:778–80. · doi:10.1111/j.1651-2227.2009.01647.x
  33. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90:220–4. · DOI · Paper page
  34. Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. Curr Opin Allergy Clin Immunol. 2017;17:398–404. · DOI
  35. Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46:1135–9. · DOI · Paper page
  36. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20–6. · DOI
  37. Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Müller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170:539–49. · DOI
  38. Choi YB, Yi DY. Fatal case of hemophagocytic lymphohistiocytosis associated with group B streptococcus sepsis: a case report. Medicine (Baltimore). 2018;97:e12210. · doi:10.1097/md.0000000000012210
  39. Sağlam B, Albayrak M, Acar A, Yıldız A, Maral S, Tığlıoğlu M, et al. Q fever as a rare cause of hemophagocytic lymphohistiocytosis: case report. Transfus Apher Sci. 2020;28:102747. · doi:10.1016/j.transci.2020.102747
  40. Miyoshi Y, Yoshioka S, Gosho H, Miyazoe S, Suenaga H, Aoki M, et al. A neonatal case of coxsackievirus B3 vertical infection with symptoms of hemophagocytic lymphohistiocytosis. ID Cases. 2020;20:e00738.
  41. Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017;16:743–9. · DOI
  42. Mărginean MO, Molnar E, Chinceşan MI. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a small child: a case report. Medicine (Baltimore). 2020;99:e18759. · doi:10.1097/md.0000000000018759
  43. Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood. 2005;106:3090–6. · DOI
  44. Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza pandemics: past, present and future. J Formos Med Assoc. 2006;105:1–6. · DOI · Paper page
  45. Mao H, Liu Y, Sia SF, Peiris JSM, Lau YL, Tu W. Avian influenza virus directly infects human natural killer cells and inhibits cell activity. Virol Sin. 2017;32:122–9. · DOI
  46. Brisse E, Wouters CH, Andrei G, Matthys P. How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis. Front Immunol. 2017;8:1102. · DOI
  47. Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130:2728–38. · DOI · Paper page
  48. Gauiran DTV, Cheng PVCY, Pagaduan CRP, Santos MCM. Autoimmune-associated hemophagocytosis and myelofibrosis in a newly diagnosed lupus patient: case report and literature review. Case Rep Hematol. 2019;2019:3879148.
  49. Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P, Cervera R, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus. 2013;22:1327–35. · DOI
  50. Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H, Szekanecz Z, et al. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol. 2013;44:23–30. · DOI
  51. Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation 2020;[Online ahead of print]. https://doi.org/10.1161/CIRCULATIONAHA.120.047419. · DOI · Paper page
  52. Singer M. The new sepsis consensus definitions (Sepsis-3): the good, the not-so-bad, and the actually-quite-pretty. Intensive Care Med. 2016;42:2027–9. · DOI
  53. Knaak C, Schuster FS, Spies C, Vorderwülbecke G, Nyvlt P, Schenk T, et al. Hemophagocytic lymphohistiocytosis in critically ill patients. Shock. 2020;53(6):701–9. · DOI
  54. Simon DW, Halstead ES, Davila S, Kernan KF, Clark RSB, Storch G, et al. DNA viremia is associated with hyperferritinemia in pediatric sepsis. J Pediatr. 2019;213:82–87.e2. https://doi.org/10.1016/j.jpeds.2019.06.033. · DOI
  55. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clin Exp Immunol. 2018;191:220–8. · DOI
  56. Li R, Luo C, Mines M, Zhang J, Fan GH. Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain. J Biol Chem. 2006;281:37616–27. · DOI
  57. Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30:84–9. · DOI · Paper page
  58. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 1800;2010:760–9.
  59. ten Kate J, Drenth JP, Kahn MF, van Deursen C. Iron saturation of serum ferritin in patients with adult onset Still's disease. J Rheumatol. 2001;28:2213–5.
  60. Khodour Y, Kaguni LS, Stiban J. Iron-sulfur clusters in nucleic acid metabolism: varying roles of ancient cofactors. Enzymes. 2019;45:225–56. https://doi.org/10.1016/bs.enz.2019.08.003. · DOI
  61. Jia Z, Liming Y, Ren Z, Wu L, Wang J, Guo J, et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 2019;47:6538–50. · DOI · Paper page
  62. Thursz M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut. 2007;56(5):613–4. https://doi.org/10.1136/gut.2006.113076. · DOI
  63. Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology. 2005;41(5):1074–84. https://doi.org/10.1002/hep.20683. · DOI · Paper page
  64. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med. 2005;11(4 Suppl):S33–44. https://doi.org/10.1038/nm1221. · DOI · Paper page
  65. Haider BA, Spiegelman D, Hertzmark E, Sando D, Duggan C, Makubi A, et al. Anemia, iron deficiency, and Iron supplementation in relation to mortality among HIV-infected patients receiving highly active antiretroviral therapy in Tanzania. Am J Trop Med Hyg. 2019;100(6):1512–20. https://doi.org/10.4269/ajtmh.18-0096. · DOI
  66. Liu W, Zhang S, Nekhai S, Liu S. Depriving Iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Curr Clin Microbiol Rep. 2020;20:1–7. https://doi.org/10.1007/s40588-020-00140-w. · DOI
  67. Rigamonti L, Ariotti S, Losana G, Gradini R, Russo MA, Jouanguy E, et al. Surface expression of the IFN-gamma R2 chain is regulated by intracellular trafficking in human T lymphocytes. J Immunol. 2000;164:201–7. · DOI
  68. Brock JH, Mulero V. Cellular and molecular aspects of iron and immune function. Proc Nutr Soc. 2000;59:537–40. · DOI
  69. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290–301. · DOI · Paper page
  70. Lachmann G, Knaak C, von Haefen C, Paeschke N, Meisel C, Nyvlt P, et al. Diagnostic biomarkers for adult haemophagocytic lymphohistiocytosis in critically ill patients (HEMICU): a prospective observational study protocol. BMJ Open. 2019;9:e032695. · doi:10.1136/bmjopen-2019-032695
  71. Møller HJ. Soluble CD163. Scand J Clin Lab Inv. 2012;72:1–13. · DOI · Paper page
  72. Vishwanath P, Prashant A, Nataraj SM, Kotekar N, Doddamani P. Can soluble CD163 predict outcome of patients with acute respiratory distress from mechanical ventilation? A pilot study. Indian J Crit Care Med. 2013;17:355–8. · doi:10.4103/0972-5229.123445
  73. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. · DOI · Paper page
  74. Schaer D, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6–10. · DOI · Paper page
  75. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.
  76. Sakumura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;110:459–65. · DOI
  77. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. sCD163 in AOSD, a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177–83. · DOI
  78. Nishino A, Katsumata Y, Kawasumi H, Hirahara S, Kawaguchi Y, Yamanaka H. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. Lupus. 2019;28:986–94. · DOI
  79. Gao Z, Wang Y, Wang J, Zhang J, Wang Z. Soluble ST2 and CD163 as potential biomarkers to differentiate primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome. Mediterr J Hematol Infect Dis. 2019;11:e2019008.
  80. Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatol Online J. 2020;18:2. · DOI
  81. Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonE’-Paut I, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2018;70:409–19. · DOI
  82. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191–201. · DOI · Paper page
  83. Le Lan C, Loréal O, Cohen T, et al. Redox active plasma iron inC282Y/C282Y hemochromatosis. Blood. 2005;105(11):4527–31. · DOI · Paper page
  84. Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014 Jul;91(1):64–73. https://doi.org/10.1016/j.critrevonc.2014.01.006. · DOI
  85. Traoré HN, Meyer D. The effect of iron overload on in vitro HIV-1 infection. J Clin Virol. 2004;(Suppl 1):S92–8. · DOI
  86. van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ. Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol. 2001;20:141–7. · DOI
  87. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis. 2000;181:484–90. · DOI
  88. Crowe WE, Maglova LM, Ponka P, Russell JM. Human cytomegalovirus-induced host cell enlargement is iron dependent. Am J Physiol Cell Physiol. 2004;287:C1023–30. · DOI
  89. Bayraktar Y, Koseoglu T, Somner C, Kayhan B, Temizer A, Uzunalimoglu B, et al. The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. J Viral Hepat. 1996;3:129–35. · DOI
  90. Mateos F, González C, Dominguez C, Losa JE, Jimenez A, Pérez-Arellano JL. Elevated non-transferrin bound iron in the lungs of patients with Pneumocystis carinii pneumonia. J Inf Secur. 1999;38:18–21.
  91. Arantes JM, Francisco AF, de Abreu Vieira PM, Silva M, Araújo MSS, de Carvalho AT, et al. Trypanosoma cruzi: desferrioxamine decreases mortality and parasitemia in infected mice through a trypanostatic effect. Exp Parasitol. 2011;128:401–8. · DOI
  92. Kazmierski WM, Wolberg G, Wilson JG, Smith SR, Williams DS, Thorp HH, et al. Iron chelates bind nitric oxide and decrease mortality in an experimental model of septic shock. Proc Natl Acad Sci U S A. 1996;93:9138–41. · DOI
  93. Wang S, Liu C, Pan S, Miao Q, Xue J, Xun J, et al. Deferoxamine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxic shock in mice. Biochem Biophys Res Commun. 2015;465:305–11. · DOI
  94. Adams PC. Chelation therapy for secondary iron overload: is the primary effect less iron or less liver fibrosis? Gastroenterology. 2011;141:1142–3. · DOI
  95. Adel N, Mantawy EM, El-Sherbiny DA, El-Demerdash E. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: a mechanistic approach. Toxicol Appl Pharmacol. 2019;382:114748. · DOI
  96. Mohammed A, Abd Al Haleem EN, El-Bakly WM, El-Demerdash E. Deferoxamine alleviates liver fibrosis induced by CCl4 in rats. Clin Exp Pharmacol Physiol. 2016;43:760–8. · DOI
  97. Darwish SF, El-Bakly WM, El-Naga RN, Awad AS, El-Demerdash E. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: impact on interferon therapy. Biochem Pharmacol. 2015;98:231–42. · DOI
  98. Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015;30:638–45. · doi:10.1111/jgh.12720
  99. Tamura K, Uneda K, Azushima K, Wakui H, Haruhara K. Possible therapeutic impact of the iron chelation on renal fibrosis. Hypertens Res. 2015;38:455–6. · DOI
  100. Li LF, Huang CC, Liu YY, Lin HC, Kao KC, Yang CT, et al. Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor. Transl Res. 2011;157:293–305. · doi:10.1016/j.trsl.2010.12.009
  101. Huang LT, Chou HC, Wang LF, Chen CM. Tissue plasminogen activator attenuates ventilator-induced lung injury in rats. Acta Pharmacol Sin. 2012;33:991–7. · doi:10.1038/aps.2012.66
  102. Zhu W, Huang Y, Ye Y, Wang Y. Deferoxamine preconditioning ameliorates mechanical ventilation-induced lung injury in rat model via ROS in alveolar macrophages: a randomized controlled study. BMC Anesthesiol. 2018;18:116. · DOI
  103. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun. 2020;111:102468. https://doi.org/10.1016/j.jaut.2020.102468. · DOI · Paper page
  104. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;19(6):102538. https://doi.org/10.1016/j.autrev.2020.102538. · DOI · Paper page

Cited by

See all 208

Metadata

Authors
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R.
Venue
Immunologic Research
Published
2020-07-17
Volume
68
Issue
4
Pages
213-224
ISSN
  • 0257-277X (ISSN-L)
  • 1559-0755
OpenAlex
W3042676445
Cited by
208
References
17
FWCI
5.61
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Università degli Studi di Perugia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. https://app.cochat.ai/papers/10.1007/s12026-020-09145-5
The paper
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020). COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunologic Research. https://doi.org/10.1007/s12026-020-09145-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.